Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Multi-national, Open-labelled, Randomised, Parallel Group, 4 Week run-in and 26 Weeks Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Insulin naïve Subjects With Type 2 Diabetes

NCT00469092 is registered in ClinicalTrials.gov with Novo Nordisk A/S as lead sponsor.

NCT NCT00469092
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00469092 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Multi-national, Open-labelled, Randomised, Parallel Group, 4 Week run-in and 26 Weeks Treat-to-target Comparison of Biphasic Insulin Aspart 30 Once Daily Versus Insulin Glargine Once Daily Both in Combination With Metformin and Glimepiride in Insulin naïve Subjects With Type 2 Diabetes
Lead sponsor
Novo Nordisk A/S
Phase
Phase 4
Overall status
Completed
Start date
May 31, 2007
Completion date
April 30, 2008
Enrollment
480 (actual)
Sites
69

Conditions

As the registry lists them; a condition with its own page is linked.

diabetes, diabetes mellitus, type 2